Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No.
Bounameaux
H
H
Division of Angiology and Hemostasis, Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland. henri.bounameaux@medecine.unige.ch
de Moerloose
P
P
D000925:Anticoagulants / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D016903:Drug Monitoring; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D010314:Partial Thromboplastin Time; D017410:Practice Guidelines as Topic; D012306:Risk; D013923:Thromboembolism / Q000209:etiology
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight